Genetic Technologies Ltd (ASX: GTG) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Genetic Technologies Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.67 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 145.42 million
Earnings per share -0.008
Dividend per share N/A
Year To Date Return N/A
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Genetic Technologies Ltd (ASX: GTG)
    Latest News

    a woman
    ⏸️ Investing

    Market wipeout: Stocks crushed in $24 billion rush for the exits

    S&P/ASX 200 sinks 1.3%, but these stocks fared much worse

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    S&P/ASX 200 closes flat, but these four skyrocketed

    Read more »

    a woman
    ⏸️ Investing

    Genetic Technologies Limited soars 30%: Here's why

    Highly speculative Genetic Technologies Limited (ASX:GTG) could be one to watch

    Read more »

    GTG ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Genetic Technologies Ltd

    Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Anthony Hartman Non-Executive Director May 2025
    Mr Hartman has over 20 years of experience in financial services in Australia, NZ, UK, EU, KH and North America. He has held positions with such firms as JP Morgan Investment Management, Citigroup Inc and Macquarie Group Ltd in financial services. Anthonys experience has been in listed markets in sales, discretionary portfolio management and structured situations. He has also been involved in private equity in listed and unlisted companies in a variety of diverse industries. Anthony is a current director of ASX listed Australian Bond Exchange Holdings Ltd.
    Mr Michael Walker Executive ChairmanManaging Director May 2025
    Mr Walker brings over 20 years of leadership and compliance experience across industries, with a focus on regulatory licensing and financial services. He is the Founder and Investment Manager of Walker Capital, a boutique wealth management firm in discretionary managed portfolios and a Fixed Income Fund. Michael is also the Director and CEO of Ellerfield Financial Planning. In addition, Michael serves as one of the Responsible Managers of Walker Capital Private Wealth Pty Ltd, which operates under an Australian Financial Services Licence (AFSL).
    Mr William Anthony Musgrave Non-Executive Director May 2025
    Mr Musgrave, has 20 years of commercial experience to his role as a director at GTG. Before practicing law, he built a career in marketing, developing communications skills .
    Mr Mark Ziirsen Chief Financial OfficerCompany Secretary Jul 2024
    -
    Ms Priyamvada Sanjay Rasal (Pia) Joint Company Secretary May 2025
    -
    Mr Simon Morriss Chief Executive Officer Feb 2021
    -
    Carl Stubbings Chief Commercial Officer
    -
    Simon Morriss Chief Executive Officer
    -
    Kevin Camilleri Chief Executive Officer EasyDNA
    -
    Kathryn Andrews Chief Financial Officer
    -
    Mark Ziirsen Chief Financial OfficerCompany Secretary
    -
    Priyamvada Sanjay Rasal (Pia) Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 103,434,943 71.13%
    Mr Warwick Wright 2,440,000 1.68%
    MJGD Nominees Pty Ltd 2,008,494 1.38%
    Doma 193 Pty Ltd <Doma 193 A/C> 1,445,514 0.99%
    Rip Opportunities Pty Ltd <Pir Super Fund A/C> 1,250,000 0.86%
    Irwin Biotech Nominees Pty Ltd <Bioa A/C> 758,494 0.52%
    Mr Lei Da Tao 685,000 0.47%
    Irwin Biotech Nominees P/L <Bioa A/C> 679,209 0.47%
    Miss Susan Spiteri 557,724 0.38%
    AP 300 Pty Ltd <AP Invest A/C> 480,400 0.33%
    Monument Hill Pty Ltd 420,001 0.29%
    Mrs Helen Kamer and Mr Benjamin Kamer <Kamer Super Fund A/C> 400,000 0.28%
    Ms Carol Yan Lu 400,000 0.28%
    Alwoonee Pty Ltd <The O'Connor Super A/C> 388,959 0.27%
    Mr Wenbo Liu 377,358 0.26%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 354,066 0.24%
    Mr John Christopolous <Chrisand Family A/C> 348,000 0.22%
    Aquasafe Investments Pty Ltd <White Superfund A/C> 306,081 0.21%
    Mr Kar Leong Chong 300,000 0.21%
    Mr Md Touhidur Rahman 300,000 0.21%
    Whalecorp Pty Ltd <Whalecorp Pty Ltd S/F A/C> 300,000 0.21%

    Profile

    since

    Note